Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA

Karl Gaffney; Nicola Gullick; Kirsten MacKay; Yusuf Patel; Raj Sengupta; Tom Sheeran; Louise Hemmings; Paula Pamies

doi:10.1093/rap/rkad055

Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA

Rheumatol Adv Pract. 2023 Aug 21;7(3):rkad055. doi: 10.1093/rap/rkad055. eCollection 2023.

Authors

Karl Gaffney¹, Nicola Gullick², Kirsten MacKay³, Yusuf Patel⁴, Raj Sengupta⁵, Tom Sheeran⁶, Louise Hemmings⁷, Paula Pamies⁷

Affiliations

¹ Department of Rheumatology, Norfolk and Norwich University Hospitals, NHS Foundation Trust, Norwich, UK.
² University Hospital Coventry & Warwickshire, Warwick Medical School, University of Warwick, Coventry, UK.
³ Rheumatology, Torbay and South Devon NHS Foundation Trust, Torquay, UK.
⁴ Hull University Teaching Hospitals NHS Trust, Hull, UK.
⁵ Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK.
⁶ University of Wolverhampton, Royal Wolverhampton NHS Trust, Wolverhampton, UK.
⁷ Immunology, Novartis Pharmaceuticals UK Ltd, London, UK.

Abstract

Objectives: The aim was to evaluate retention rates for secukinumab in patients with active PsA or radiographic axial spondyloarthritis (r-axSpA) treated in routine UK clinical practice.

Methods: SERENA (CAIN457A3403) is an ongoing, non-interventional, international study of patients with moderate-to-severe chronic plaque psoriasis, active PsA or active r-axSpA, who had received secukinumab for ≥16 weeks before enrolment. The primary objective of this interim analysis was to assess treatment retention rates in patients with PsA or r-axSpA who were enrolled and followed for ≥2 years at centres in the UK. The safety analysis set includes all patients who received at least one dose of secukinumab. The target population set includes all patients who fulfilled the patient selection criteria.

Results: The safety set comprised 189 patients (PsA, n = 81; r-axSpA, n = 108), and the target population set comprised 183 patients (PsA, n = 78; r-axSpA, n = 105). In the safety set, 107 patients (45 of 81 with PsA and 62 of 108 with r-axSpA) had previously received a biologic agent. Retention rates were similar between patients with PsA and r-axSpA after 1 year (PsA 91.0%, 95% CI: 84.0, 98.0; r-axSpA 89.2%, 95% CI: 82.7, 95.7) and 2 years (PsA 77.6%, 95% CI: 67.6, 87.7; r-axSpA 76.2%, 95% CI: 67.4, 85.0) of observation. Overall, 17.5% of patients (33 of 189) experienced at least one treatment-related adverse event, and 12.7% of patients (24 of 189) discontinued secukinumab because of adverse events.

Conclusion: This analysis of real-world data from the UK demonstrates high retention rates for secukinumab over 2 years in patients with PsA or r-axSpA, with a favourable safety profile.

Keywords: PsA; drug survival; radiographic axial spondyloarthritis; real-world evidence; secukinumab.